The Manager of Operations of the Department of Pharmacy Services will assist the Director in all aspects of the day to day operations of the department to ensure the timely and accurate delivery of me...

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 clinical trial of MBX-8025. A summary of the results was presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) on November 1, 2008. MBX-8025 is an oral drug candidate that is being evaluated for the treatment of dyslipidemia.

XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain. The trial's primary objective was to compare the efficacy of two doses of Bicifadine against placebo in reducing pain associated with diabetic neuropathy. The primary endpoint of the study was the reduction in pain score during the course of treatment.

Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary liver cancer treatment for melanoma metastatic to the liver, announced that the United States Food and Drug Administration ("FDA") granted to Delcath two orphan-drug applications for the drug melphalan. Delcath was granted designations of the drug melphalan for the treatment of patients with cutaneous as well as ocular melanoma.

Tibotec recently announced long-term study results from a phase 3 clinical trial, which compared PREZISTA(R) (darunavir)/ritonavir to lopinavir/ritonavir, as part of HIV combination therapy, in lopinavir/r-naive, treatment-experienced HIV-1 infected adults. A 96-week resistance analysis from the study, known as TITAN, was presented in an oral presentation at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, UK on November 13, 2008.

African-American women are at a higher risk for ER/PR negative breast cancer. A new study, to be presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research, found that race, socioeconomic characteristics and other tumor characteristics are all important predictors of having ER/PR negative breast cancer.

A randomized clinical trial involving over 3,000 elderly people in the US found that the popular herbal supplement Gingko biloba fared no better than placebo at preventing dementia or Alzheimer's disease. The research was the work of the Ginkgo Evaluation of Memory (GEM) Study Investigators who are based at centers throughout the US, including the University of Pittsburgh, Pennsylvania, where lead author Dr Steven T DeKosky, was working at the time of the investigation.